Table 1 Demographic and clinic data

Demographic data

 Sex

 —Male

18 (75%)

 —Female

6 (25%)

  Age, years^a

64 (29–82)

  BMI, kg/m^2a

24.6 (18–37)

 ASA score

 —1–2

17 (70.8%)

 —3

7 (29.2%)

 Pretreatment CEA level

 —< 200 g/L

15 (62.5%)

 —≥ 200 g/L

5 (20.8%)

 —Missing

4 (16.7%)

Rectal tumour

 Tumour location

 —Middle

11 (45.8%)

 —Lower

13 (54.2%)

 Pretreatment T stage

 —T3

22 (91.7%)

 —T4a

2 (8.3%)

 Pretreatment N stage

 —N0

4 (16.7%)

 —N + 

20 (83.3%)

  Predictive threatened CRM (< 1 mm)

9 (37.5%)

 Liver metastases

  Number of liver metastases^a

2.5 (1–15)

 > 3 lesions

9 (37.5%)

  Size of the largest metastases^a

40 (18–100)

 > 5 cm

10 (41.7%)

  Bilobar metastases

12 (50%)

 Initial resectability

 —Resectable

19 (79.2%)

 —Potentially resectable

5 (20.8%)

Preoperative treatment

 Chemotherapy regimen

 —Folfox

10 (41.6%)

 —Folfirinox

11 (45.8%)

 —Folfiri

3 (12.5%)

 —Cetuximab/bevacizumab

6 (25%)

 Radiotherapy modalities

 —Long course (50 Gy)

21 (91.3%)

 —Short course (25 Gy)

2 (8.7%)